Loading clinical trials...

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a diagnosis of adult onset rheumatoid arthritis (RA) for at least 3 months prior to screening, as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria
•Have moderately-to-severely active RA, at screening and baseline, defined by the presence of
•* ≥6 swollen joints based on 66 joint count, and
•* ≥6 tender joints based on 68 joint count.
•Have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic DMARD (csDMARD), biologic DMARD ( bDMARD), or targeted synthetic DMARD (tsDMARD) treatment.

Exclusion Criteria

•Have Class IV RA according to ACR revised criteria.
•Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
•* poorly controlled diabetes or hypertension
•* chronic kidney disease stage IIIb, IV, or V
•* symptomatic heart failure according to New York Heart Association Class II, III, or IV
•* myocardial infarction, unstable angina pectoris, stroke or transient ischemic attack, within the past 12 months before randomization
•* severe chronic pulmonary disease, for example, requiring oxygen therapy
•* major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to,
•* systemic lupus erythematosus
•* psoriatic arthritis
+8 more criteria

Locations (131)

Accel Research Sites - Birmingham Clinical Research Unit

Birmingham, Alabama, United States

Arizona Arthritis & Rheumatology Research PLLC

Gilbert, Arizona, United States

Arizona Arthritis & Rheumatology Research, PLLC

Glendale, Arizona, United States

Arizona Arthritis & Rheumatology Research, PLLC

Mesa, Arizona, United States

Arizona Arthritis & Rheumatology Associates, PLLC

Phoenix, Arizona, United States

Medvin Clinical Research - Metyas

Covina, California, United States

St Joseph Heritage Healthcare

Fullerton, California, United States

Newport Huntington Medical Group

Huntington Beach, California, United States

Desert Medical Advances

Rancho Mirage, California, United States

Dan La, MD Inc

Tujunga, California, United States

Key Dates

Start Date

August 31, 2022

Primary Completion Date

November 20, 2023

Completion Date

January 17, 2025

Last Updated

December 4, 2025

Enrollment

491

ACTUAL participants

Conditions

Rheumatoid ArthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Interventions

Peresolimab

DRUG

Placebo

DRUG

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT06647069

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

View study

RECRUITINGPHASE2/PHASE3

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

A Study of Picankibart in Patients With Active Psoriatic Arthritis

Natural History and Development of Spondyloarthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis